STOCK TITAN

Titan Announces the Closing of Conavi’s Private Placement of Subscription Receipts and Provides Update on the Transaction

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
private placement

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) announced the closing of Conavi Medical Inc.'s private placement of subscription receipts, raising US$7.7 million in gross proceeds. This is part of the companies' amalgamation agreement for an all-stock transaction. 7,729,300 Subscription Receipts were issued at US$1.00 each, with 7,526,025 in a brokered portion led by Bloom Burton Securities Inc.

The transaction is expected to close around October 11, 2024. Titan will change its name to Conavi Medical Corp. and complete a 25-to-1 share consolidation. Titan plans to delist from the TSX and relist on the TSXV under the symbol 'CNVI'. Trading on the TSXV is expected to commence immediately after delisting from the TSX, which is anticipated around October 16, 2024.

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) ha annunciato la chiusura del collocamento privato di ricevute di sottoscrizione di Conavi Medical Inc., raccogliendo 7,7 milioni di dollari USA in proventi lordi. Questo fa parte dell'accordo di fusione delle aziende per una transazione interamente in azioni. Sono state emesse 7.729.300 ricevute di sottoscrizione a 1,00 dollaro USA ciascuna, con 7.526.025 nella porzione mediata guidata da Bloom Burton Securities Inc.

Si prevede che la transazione si chiuda intorno al 11 ottobre 2024. Titan cambierà il suo nome in Conavi Medical Corp. e completerà una consolidazione delle azioni 25 a 1. Titan prevede di ritirarsi dal TSX e di essere quotata nuovamente sul TSXV con il simbolo 'CNVI'. Le negoziazioni sul TSXV dovrebbero iniziare immediatamente dopo il ritiro dal TSX, che è previsto intorno al 16 ottobre 2024.

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) anunció el cierre de la colocación privada de recibos de suscripción de Conavi Medical Inc., recaudando 7.7 millones de dólares estadounidenses en ingresos brutos. Esto es parte del acuerdo de fusión entre las empresas para una transacción completamente en acciones. Se emitieron 7,729,300 recibos de suscripción a 1.00 dólar estadounidense cada uno, con 7,526,025 en una porción gestionada por Bloom Burton Securities Inc.

Se espera que la transacción se cierre alrededor del 11 de octubre de 2024. Titan cambiará su nombre a Conavi Medical Corp. y completará una consolidación de acciones de 25 a 1. Titan planea retirarse del TSX y volver a listarse en el TSXV bajo el símbolo 'CNVI'. Se espera que la negociación en el TSXV comience inmediatamente después de la deslistación del TSX, que se anticipa alrededor del 16 de octubre de 2024.

Titan Medical Inc. (TSX: TMD; OTC: TMDIF)는 Conavi Medical Inc.의 전환증권에 대한 사모 배치 종료를 발표하며 770만 달러의 총 수익을 올렸습니다. 이는 전량 주식 거래에 대한 기업 합병 계약의 일부입니다. 7,729,300개의 전환증권이 각각 1.00달러의 가격으로 발행되었으며, 이 중 7,526,025개는 Bloom Burton Securities Inc.가 주관하는 중개 부분입니다.

이번 거래는 2024년 10월 11일경에 마감될 것으로 예상됩니다. Titan은 이름을 Conavi Medical Corp.로 변경하고 25대 1의 주식 통합을 완료할 예정입니다. Titan은 TSX에서 상장 폐지하고 'CNVI'라는 기호로 TSXV에 재상장할 계획입니다. TSXV에서의 거래는 TSX에서 상장 폐지된 직후 즉시 시작될 것으로 예상되며, 이는 2024년 10월 16일 경으로 예상됩니다.

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) a annoncé la clôture du placement privé de reçus de souscription de Conavi Medical Inc., levant 7,7 millions de dollars US de recettes brutes. Cela fait partie de l'accord de fusion entre les sociétés pour une transaction entièrement en actions. 7 729 300 reçus de souscription ont été émis à 1,00 dollar US chacun, dont 7 526 025 dans une portion intermédiaire dirigée par Bloom Burton Securities Inc.

La transaction devrait se conclure aux alentours du 11 octobre 2024. Titan changera son nom en Conavi Medical Corp. et effectuera une consolidation des actions de 25 pour 1. Titan prévoit de se retirer de la TSX et de se relister à la TSXV sous le symbole 'CNVI'. La négociation sur le TSXV devrait commencer immédiatement après la radiation de la TSX, ce qui est prévu autour du 16 octobre 2024.

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) hat den Abschluss der Privatplatzierung von Beitrittsquittungen von Conavi Medical Inc. bekanntgegeben und dabei 7,7 Millionen US-Dollar an Bruttoerlösen gesammelt. Dies ist Teil des Fusionsvertrags der Unternehmen für eine reine Aktienübertragung. Insgesamt wurden 7.729.300 Beitrittsquittungen zu einem Preis von 1,00 US-Dollar ausgegeben, davon 7.526.025 in einem von Bloom Burton Securities Inc. geleiteten vermittelten Teil.

Der Abschluss der Transaktion wird für etwa den 11. Oktober 2024 erwartet. Titan wird seinen Namen in Conavi Medical Corp. ändern und eine Aktienkonsolidierung im Verhältnis 25 zu 1 durchführen. Titan plant, sich von der TSX abzulisten und unter dem Symbol 'CNVI' an der TSXV neu zu listen. Der Handel an der TSXV wird voraussichtlich unmittelbar nach der Delistung von der TSX beginnen, was um den 16. Oktober 2024 erwartet wird.

Positive
  • Raised US$7.7 million in gross proceeds through private placement
  • Transaction expected to close on October 11, 2024
  • Received conditional approval from TSXV for listing under symbol 'CNVI'
Negative
  • 25-to-1 share consolidation planned, potentially affecting share value
  • Delisting from TSX, which may impact some investors
  • Complex transaction structure may create short-term uncertainty

TORONTO, Ontario, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that, in connection with its amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”), Conavi has closed its previously announced concurrent private placement of subscription receipts (“Subscription Receipts”) for gross proceeds of US$7.7 million (the “Offering”).

Pursuant to the Offering, Conavi issued 7,729,300 Subscription Receipts (7,526,025 of which were issued in a brokered portion of the Offering, with the remainder in a concurrent, non-brokered private placement) at a price of US$1.00 per Subscription Receipt to certain institutional and accredited investors, including Conavi’s lead investors and principal shareholders, Carlyle Services Limited Liability Company, CPOINT Capital Corp. and Juno Pharmaceuticals LP. The brokered portion of the Offering was led by Bloom Burton Securities Inc. (the “Agent”) as exclusive agent and financial advisor. Each Subscription Receipt shall entitle the holder to receive, upon satisfaction of certain escrow release conditions (including satisfaction or waiver of the closing conditions to the Transaction) ("Escrow Release Conditions"), and without payment of additional consideration, one unit in the capital of Conavi consisting of one voting common share in the capital of Conavi (each, a “Conavi Share”) and one warrant of Conavi (each, a “Conavi Warrant”) to purchase one Conavi Share at an exercise price of US$1.25 per Conavi Share. At the effective time of the completion of Conavi’s proposed reverse take-over of Titan (“Closing”), as described in the press releases of Titan dated March 18, 2024, with subsequent amendments to the Amalgamation Agreement announced on May 29, 2024, July 5, 2024 and August 14, 2024, each Conavi Share and Conavi Warrant acquired upon conversion of the Subscription Receipts will be automatically exchanged and adjusted, on the basis of the Exchange Ratio (as defined in the Amalgamation Agreement) for equivalent securities in the capital of the reporting issuer resulting from the completion of the Transaction (the "Resulting Issuer"), being common shares in the capital of the Resulting Issuer (each a "Resulting Issuer Share") and common share purchase warrants of the Resulting Issuer (each whole common share purchase warrant, a "Resulting Issuer Warrant"). The Resulting Issuer Warrants will expire five years after completion of the Transaction.

In connection with the Offering, the Agent is entitled to a cash fee equal to 7.0% of the gross proceeds in respect of the brokered portion of the Offering. As additional compensation, the Agent has been issued 35,329 broker warrants (the “Broker Warrants”). Each Broker Warrant shall be exercisable for purchase of one Conavi Share at a price of US$1.00 per Conavi Share for 24 months following Closing of the Transaction, and will be automatically exchanged and adjusted, on the basis of the Exchange Ratio (as such term is defined in the joint management information circular for the Transaction dated August 30, 2024, which may be viewed under Titan’s profile at www.sedarplus.com) (the “MIC”), for broker warrants of the Resulting Issuer. Notwithstanding the foregoing, the Agent did not receive Broker Warrants with respect to subscriptions from Carlyle Services Limited Liability Company, CPOINT Capital Corp. and Juno Pharmaceuticals LP, and the Agent’s cash fee entitlement is 3.5% of the gross proceeds raised from such subscriptions.

The net proceeds of the Offering and 50% of the Agent’s cash fee are being held in escrow and, upon the satisfaction or waiver of the Escrow Release Conditions, the net proceeds will be released to Conavi and the remaining portion of the Agent’s cash fee will be released to the Agent.

Additional details of the Offering, including the terms of share consolidations to be carried out by each of Titan and Conavi, and additional details concerning the terms of the Transaction and the Exchange Ratio, are disclosed in the MIC.

Conavi intends to use the proceeds of the Offering for product research and development and production activities for Novasight 3.0, ongoing commercialization activities, and for working capital and general corporate purposes.

The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referenced in this press release, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The closing of the Transaction, which is subject to the satisfaction or waiver of a number of customary closing conditions, is expected to take place on or around October 11, 2024. In connection with closing of the Transaction, Titan is expected to change its name to Conavi Medical Corp. and to complete a 25-to-1 share consolidation. In addition, further to its press release dated, September 30, 2024, Titan intends to voluntarily delist from the Toronto Stock Exchange (“TSX”) and to apply to re-list its shares on the TSX Venture Exchange (“TSXV”).

Following Closing, it is expected that Titan’s shares will continue to trade on a pre-consolidation and pre-Transaction basis for two or three business days following Closing of the Transaction while the parties seek the final approval of the TSX and the TSXV. Upon receipt of such approvals, Titan’s common shares are expected to be delisted from the TSX effective as of close of markets on or around October 16, 2024. Titan has received conditional approval from the TSXV for the listing of the Resulting Issuer Shares under the symbol “CNVI”, and subject to final approval of the TSXV, trading on the TSXV (which will give effect to Titan’s name change, 25-to-1 share consolidation and Closing of the Transaction) is expected to commence immediately on the trading day following delisting from the TSX without any interruption in trading. A further update regarding the process of delisting from the TSX and relisting on the TSXV will be provided upon Closing of the Transaction.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical

Conavi Medical Inc. is a privately-owned company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit http://www.conavi.com/.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to the continued work of Titan and Conavi towards the completion of the Transaction.

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration; the satisfaction of the Escrow Release Conditions; the receipt of final required approvals from the TSX Venture Exchange in connection with the Transaction or change of listing and the timing thereof; the successful completion of the Transaction and other factors listed in the “Risk Factors” sections of Titan’s Annual Information Form for the fiscal year ended December 31, 2023 and the MIC (which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contacts

Titan Medical Inc.
Chien Huang
Chief Financial Officer
investors@titanmedicalinc.com

Conavi Medical Inc.
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

###

521846245v.4


FAQ

What is the gross proceeds amount raised by Conavi's private placement for Titan Medical (TMDIF)?

Conavi Medical Inc. raised US$7.7 million in gross proceeds through a private placement of subscription receipts in connection with its amalgamation agreement with Titan Medical Inc. (TMDIF).

When is the expected closing date for Titan Medical's (TMDIF) transaction with Conavi?

The transaction between Titan Medical Inc. (TMDIF) and Conavi Medical Inc. is expected to close on or around October 11, 2024.

What will be the new name and stock symbol for Titan Medical (TMDIF) after the transaction?

After the transaction, Titan Medical Inc. (TMDIF) is expected to change its name to Conavi Medical Corp. and trade on the TSXV under the new symbol 'CNVI'.

What is the share consolidation ratio announced for Titan Medical (TMDIF)?

Titan Medical Inc. (TMDIF) announced a 25-to-1 share consolidation to be completed in connection with the closing of the transaction with Conavi Medical Inc.

TITAN MEDICAL INC ORD

OTC:TMDIF

TMDIF Rankings

TMDIF Latest News

TMDIF Stock Data

4.10M
71.8%
1.33%
Medical Devices
Healthcare
Link
United States of America
Toronto